| Product Code: ETC10765644 | Publication Date: Apr 2025 | Updated Date: Nov 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | No. of Pages: 65 | No. of Figures: 34 | No. of Tables: 19 | |
The Netherlands continues to see a steady flow of pemetrexed import shipments in 2024, with top exporters including Germany, USA, Ireland, Belgium, and Italy. The Herfindahl-Hirschman Index (HHI) indicates a moderate concentration in the market. The compound annual growth rate (CAGR) from 2020 to 2024 stands at a healthy 5.02%, with a slight growth rate of 0.84% from 2023 to 2024. This data suggests a stable and growing market for pemetrexed imports in the Netherlands.

1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Netherlands Pemetrexed Market Overview |
3.1 Netherlands Country Macro Economic Indicators |
3.2 Netherlands Pemetrexed Market Revenues & Volume, 2021 & 2031F |
3.3 Netherlands Pemetrexed Market - Industry Life Cycle |
3.4 Netherlands Pemetrexed Market - Porter's Five Forces |
3.5 Netherlands Pemetrexed Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.6 Netherlands Pemetrexed Market Revenues & Volume Share, By Mechanism of Action, 2021 & 2031F |
3.7 Netherlands Pemetrexed Market Revenues & Volume Share, By Combination Therapy, 2021 & 2031F |
3.8 Netherlands Pemetrexed Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.9 Netherlands Pemetrexed Market Revenues & Volume Share, By Administration Route, 2021 & 2031F |
4 Netherlands Pemetrexed Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing incidence of lung cancer in the Netherlands |
4.2.2 Growing adoption of pemetrexed as a preferred treatment option for lung cancer |
4.2.3 Advancements in healthcare infrastructure and access to innovative therapies |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval and market entry |
4.3.2 Pricing pressures and reimbursement challenges in the pharmaceutical market |
5 Netherlands Pemetrexed Market Trends |
6 Netherlands Pemetrexed Market, By Types |
6.1 Netherlands Pemetrexed Market, By Indication |
6.1.1 Overview and Analysis |
6.1.2 Netherlands Pemetrexed Market Revenues & Volume, By Indication, 2021 - 2031F |
6.1.3 Netherlands Pemetrexed Market Revenues & Volume, By Non-Small Cell Lung Cancer, 2021 - 2031F |
6.1.4 Netherlands Pemetrexed Market Revenues & Volume, By Mesothelioma, 2021 - 2031F |
6.1.5 Netherlands Pemetrexed Market Revenues & Volume, By Breast Cancer, 2021 - 2031F |
6.1.6 Netherlands Pemetrexed Market Revenues & Volume, By Colorectal Cancer, 2021 - 2031F |
6.1.7 Netherlands Pemetrexed Market Revenues & Volume, By Pancreatic Cancer, 2021 - 2031F |
6.2 Netherlands Pemetrexed Market, By Mechanism of Action |
6.2.1 Overview and Analysis |
6.2.2 Netherlands Pemetrexed Market Revenues & Volume, By Antifolate, 2021 - 2031F |
6.2.3 Netherlands Pemetrexed Market Revenues & Volume, By DNA Synthesis Inhibition, 2021 - 2031F |
6.2.4 Netherlands Pemetrexed Market Revenues & Volume, By Enzyme Targeting, 2021 - 2031F |
6.2.5 Netherlands Pemetrexed Market Revenues & Volume, By Cell Growth Suppression, 2021 - 2031F |
6.2.6 Netherlands Pemetrexed Market Revenues & Volume, By Purine Synthesis Blockade, 2021 - 2031F |
6.3 Netherlands Pemetrexed Market, By Combination Therapy |
6.3.1 Overview and Analysis |
6.3.2 Netherlands Pemetrexed Market Revenues & Volume, By Platinum-Based Chemotherapy, 2021 - 2031F |
6.3.3 Netherlands Pemetrexed Market Revenues & Volume, By Immunotherapy, 2021 - 2031F |
6.3.4 Netherlands Pemetrexed Market Revenues & Volume, By Radiation Therapy, 2021 - 2031F |
6.3.5 Netherlands Pemetrexed Market Revenues & Volume, By Personalized Medicine, 2021 - 2031F |
6.3.6 Netherlands Pemetrexed Market Revenues & Volume, By Monoclonal Antibodies, 2021 - 2031F |
6.4 Netherlands Pemetrexed Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 Netherlands Pemetrexed Market Revenues & Volume, By Hospitals, 2021 - 2031F |
6.4.3 Netherlands Pemetrexed Market Revenues & Volume, By Oncology Clinics, 2021 - 2031F |
6.4.4 Netherlands Pemetrexed Market Revenues & Volume, By Specialty Clinics, 2021 - 2031F |
6.4.5 Netherlands Pemetrexed Market Revenues & Volume, By Research Institutes, 2021 - 2031F |
6.4.6 Netherlands Pemetrexed Market Revenues & Volume, By Pharmaceutical Companies, 2021 - 2031F |
6.5 Netherlands Pemetrexed Market, By Administration Route |
6.5.1 Overview and Analysis |
6.5.2 Netherlands Pemetrexed Market Revenues & Volume, By Intravenous, 2021 - 2031F |
6.5.3 Netherlands Pemetrexed Market Revenues & Volume, By Injection, 2021 - 2031F |
6.5.4 Netherlands Pemetrexed Market Revenues & Volume, By IV Infusion, 2021 - 2031F |
6.5.5 Netherlands Pemetrexed Market Revenues & Volume, By Cancer Treatment Centers, 2021 - 2031F |
6.5.6 Netherlands Pemetrexed Market Revenues & Volume, By Hospital Pharmacy, 2021 - 2031F |
7 Netherlands Pemetrexed Market Import-Export Trade Statistics |
7.1 Netherlands Pemetrexed Market Export to Major Countries |
7.2 Netherlands Pemetrexed Market Imports from Major Countries |
8 Netherlands Pemetrexed Market Key Performance Indicators |
8.1 Average time from drug approval to market launch |
8.2 Patient adherence and persistence rates for pemetrexed therapy |
8.3 Number of clinical trials evaluating pemetrexed in different lung cancer subtypes |
8.4 Adoption rate of precision medicine approaches in lung cancer treatment |
8.5 Number of collaborations between pharmaceutical companies and research institutions for pemetrexed research |
9 Netherlands Pemetrexed Market - Opportunity Assessment |
9.1 Netherlands Pemetrexed Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.2 Netherlands Pemetrexed Market Opportunity Assessment, By Mechanism of Action, 2021 & 2031F |
9.3 Netherlands Pemetrexed Market Opportunity Assessment, By Combination Therapy, 2021 & 2031F |
9.4 Netherlands Pemetrexed Market Opportunity Assessment, By End User, 2021 & 2031F |
9.5 Netherlands Pemetrexed Market Opportunity Assessment, By Administration Route, 2021 & 2031F |
10 Netherlands Pemetrexed Market - Competitive Landscape |
10.1 Netherlands Pemetrexed Market Revenue Share, By Companies, 2024 |
10.2 Netherlands Pemetrexed Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here